SAR-442257

N/A

Report date: 2026/03/19 16:52:36

Base Information

Drug NameSAR-442257

Drug Alias NameSAR-442257

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-CD3Anti-CD28Anti-CD38

TargetsT cell surface glycoprotein CD3T-cell-specific surface glycoprotein CD28Lymphocyte differentiation antigen CD38

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCzechiaUnited StatesNorway +[5]

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesSanofi

China Registration ClassN/A

Develop Information

Active CompaniesSanofi

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A